CPH is up 11.6% today on volume of 2mill approx this morning on turnover of about 2.5% of shares issued.Most people may still be on holiday.
Printable View
Definitely been a good week and start to the year but learning from some of the stocks on the nzx I am a bit cautious and will sell if it looks a bit risky. I have 15% of portfolio in MC stocks so not too exposed
http://www.abc.net.au/news/2018-01-0...market/9302524
CPH ended up 20% for the day with 6.5% of shares on issue traded. MMMMMM is someone building a stake?
The ANN from OZ to make OZ the premiere world supplier of cannabis product seems to have lit a fire
ASX Announcement 11 May 2017
Creso signs Letter of Intent with LeafCann to significantly expand Creso’s future offering to the Australian market
Highlights:
Creso signs strategic agreement with pre-eminent Australian medicinal cannabis producer LeafCann
LeafCann will supply GMP-standard cannabis and hemp-derived materials to Creso to produce therapeutic products for the human and animal health markets
Partnership further advances Creso’s leadership position in the growing Australian medicinal cannabis industry
The two parties will also work together on joint product development
This agreement comes soon after Creso became the first to successfully import
medicinal cannabis products into Australia under the new Government rules
Creso Pharma Limited (ASX:CPH, “Creso” or the “Company”) is pleased to announce that it has signed a binding Letter of Intent (LOI) with Australian medicinal cannabis producer, LeafCann Group Pty Ltd (LeafCann), to accelerate the development and commercialisation of locally manufactured medicinal cannabis products in Australia.
Through the strategic agreement, LeafCann will supply Creso with cannabis and/or hemp-derived materials to Good Manufacturing Practice (GMP) standards, which will be used to develop, manufacture, sell and commercialise Creso’s pharmaceutical-grade therapeutic products for the human and animal health markets in Australia. The parties will also work together on joint product development.
The partnership strengthens Creso’s strategic leadership position in the sector and the Company is well placed to capitalise on the growth in the Australian market following federal and state legislative changes to support research, cultivation and production of medicinal cannabis.
Creso became the first company to successfully import medicinal cannabis products into Australia, as announced on the ASX on May 2, 2017. There is growing demand for medicinal cannabis products in Australia as acceptability grows. Creso’s ability to access locally cultivated and manufactured product, produced to the highest grade pharmaceutical quality in Australia, will be instrumental in filling this unmet market need.
“We are delighted to have the opportunity to work with LeafCann, a pioneer of the Australian medicinal cannabis industry. The quality of supply that LeafCann will provide will help us manufacture products that meet international pharmaceutical standards,” said Creso’s Chief Operating Officer, David Russell.
“The depth of Pharmaceutical experience and expertise that Creso brings to the industry sets us apart from the competition, and we are uniquely placed to become a leader in the market and to help shape the development of the industry.”
LeafCann is an Australian-based medicinal cannabis grower established by Co-founders Chris Nasr and Elisabetta Faenza. Mr Nasr and Ms Faenza came together to form LeafCann, driven by personal experiences with chronic illness and pain. Supported by the expertise of Dr Jaroslav Boublik, PhD (Med) as LeafCann group CEO and Visage invest financiers, LeafCann’s goal is to provide Australians with access to safe, reliable and affordable medicinal cannabis.
"We are very excited to be moving forward with Creso Pharma through this collaborative partnership, ensuring ongoing patient access and Australian industry and product development,” said Co-founder of LeafCann Group Chris Nasr.
Creso CEO and Co-founder Dr. Miri Halperin Wernli added, “Creso and LeafCann will work together in a patient oriented manner with commitment to encourage and maintain a pioneering spirit fostering the true nature of innovation from which cutting edge ideas will be translated into evidence-based therapeutic solutions.”
Another lovely day on the ASX - AC8 up yet another ~30-40% second day in a row!, CPH - ~5%,
MMJ up 9%. I'm up 50% in just over a week
All the OZ pot stocks have gone higher man(ha ha) since the Fed ann .They all have potential-- the competition is going to get tuff. There may be room for all or not time will tell.The plant itself is not difficult to grow and has a rapid yield cycle (its grows like a weed ).The real gains will be in the proprietary applications and distribution thereof.
Recreational use in the markets that allow would be much much bigger than medicinal market and the profit margins could be immense.It is extremely low tech for recreational and distribution chains would be crucial to profit margins.So management and the scientists will be the determining factors
Ac8 has rocketed in the last week 78.5 to 185 they seem to have the goods .I dont own any . CPH has gone up about 50% in the same timeframe
What medical stocks are in the 2018 ASX competition closing sunday?